Parsaclisib Not Yet Recruiting Phase 3 Trials for Post Polycythemia Vera Myelofibrosis / Post Essential Thrombocythaemia Myelofibrosis / Agnogenic Myeloid Metaplasia / Primary Myelofibrosis (PMF) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04816565To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)